日本化学療法学会雑誌第55巻第S-1号
|
|
|
- えつと さわい
- 7 years ago
- Views:
Transcription
1 Key words I
2 γ
3 II
4 Table. FertilitydataonmaleratstreatedoralywithGRNXinthestudyoffertilityandearlyembryonic developmenttoimplantation No.ofmaleratsexamined Copulationrate(%) Impregnationrate(%) No.ofsperms( 6 /gcauda) Motilityofsperms(%) Swimmingspeedofsperms (μ m/sec.) Abnormalsperm ratio(%) ±.5 88.±..8±.5.± ±.9 * 9.6±5.8.5±5..6±. 6.9±8. 9.8±7..±8..±. Mean±S.D. Significantdiferencefrom control: *,p<.5(student st-testoraspin-welchtest) ± ±.8.±5. 5.7±8. Table. FertilityandcaesareansectiondataonfemaleratstreatedoralywithGRNXinthestudyof fertilityandearlyembryonicdevelopmenttoimplantation 6 5, No.offemaleratsexamined Estrouscycle(days) Daysfrom matingtocopulation Copulationrate(%) Pregnancyrate(%) No.ofcorporalutea No.ofimplantations Implantationrate(%) No.ofliveembryos Deadorresorbedembryos(%).±..8± ±.6 6.7±.6 8.6±8.5 5.±.9 9.±8..±.7.± ±. 6.±. 8.8±..8±.6 7.5±7..±..±. 9.9±.7 6.9±. 86.±. 5.7±. 7.±6.7.±..8± ±. 6.5±. 8.7±8. 5.6±.9 5.±6.8 Mean±S.D.
5 Table. ReproductivefindingsonratdamstreatedoralywithGRNXinthestudyfor efectsonpre-andpostnataldevelopment,includingmaternalfunction 6 5, No.ofdams Gestationperiod(days) Deliveryrate(%) No.ofimplantations.± ±.9 7.±. 5.±. 9.± ±5. 8.±. 5.±. Mean±S.D. Table. Fofspringdataatbirthandduringlactationperiodobtainedfrom ratdamstreatedoralywithgrnxinthestudyfor efectsonpre-andpostnataldevelopment,includingmaternalfunction Birthrate(%) No.ofliveofspringatbirth Sexratio[Male/(Male+ Female)] ViabilityonDay(%) ViabilityonDay(%) Bodyweight(g) Day (Male/Female) Day Day 7 Day Day (SkeletalobservationonDay) No.offetuseswithskeletalanomalies Fusionofcervicalvertebralarches No.offetuseswithskeletalvariations Cervicalvertebralbody Dumbbelshape Spliting Unilateralformation Thoracicvertebralbody Dumbbelshape 5lumbarvertebrae Sacralization Cervicalrib Lumbarrib Shorteningofthrib Extrasternebrae Degreeofossification 8.±8..7±5..5±.7 99.±.5 99.±.9 7.7/6.7./. 8.69/ / /59. (%) (7.9%) ±9..9±.5.5±.6 98.±.5 ±. 6.97/6.5./.5 8.6/7. 6./.9 6.9/59. (%) (.5%) * ±9.9.±5..5±. 98.8± ± * /6. *. * /9.58 * 7.7 * /6.7 * 5. ** /.7 6. * /56.7 (%) (.6%) Mean±S.D. :Normal. Significantdiferencefrom control: *,p<.5; **,p<.(student st-testoraspin-welchtest) * 7 6, 89.6±7.8.±..8±.8 97.± ± /6.9.79/.6 7.8/ * / /58.5 (.7%) 9(.8%) * *
6 Table5. OrganweightsofFofspringobtainedfrom ratdamstreatedoralywithgrnxinthestudyforefectson pre-andpostnataldevelopment,includingmaternalfunctioninrats (AutopsyonDay) Maingenitalorganweights(g) Male Testis Epididymis Prostate Seminalvesicle Female Ovary Cecum weights(g) Male Female (AutopsyonDay7) Maingenitalorganweights(g) Male Testis Epididymis Female Ovary (Autopsyafterreproductive abilityexamination) Maingenitalorganweights(g) Male Testis Epididymis Female Ovary.±.5.5±.8.±.8.5±.6.8±..5±.7.9±.5.9±.5.9±.66.9±.9.7±.5.6±.7.±.5 6.±..±.7.±.5.±.5.±. **.±..9±.9.9±..888±.8 *.9±..7±.56.5±..±.8 5.±..±.6.±.5.±.5.8±..5±..85±.9.±.5 *.875±.7 *.7±..6±.8.5±.6.6±.5 :Normal. Significantdiferencefrom control: *,p<.5; **,p<.(student st-testoraspin-welchtest),.9±. *.6±.7.±.7.5±.6.8±..6±.6 **.6±. **.8±. **.87±.57 **.±.6.58±.7.8±.99 **.5±.5 Table6. FertilityandcaesareansectiondataonFofspringandFfetaldataobtainedfrom ratdamstreatedoraly withgrnxinthestudyforefectsonpre-andpostnataldevelopment,includingmaternalfunctioninrats Copulationrate Male Female Impregnationorpregnancyrate(%) Male Female Daysfrom matingtocopulation(female) No.ofcorporalutea No.ofimplantations Implantationrate(%) No.oflivefetuses No.ofdeadfetuses Earlystage Latestage Deadfetuses(%) Sexratio[Male/(Male+ Female)] Bodyweight(g) Male Female No.ofFfetuseswithexternalanomalies Dwarf Edema Micrognathia Imperforateanus Brachyury Filamentoustail ±. 9.5±. 6.9±.9 87.±. 5.9±..±..±..±. 6.±7..5±.5.7±..±.8 (.%) 6.8±. 9.9±. 6.±.8 8.7±7..7±.6.6±.5.6±.5.±. 9.±8..9±..±. *.±. ** (.7%) ±..±.6 7.± ±.7 6.7±.5.5±.7.5±.7.±..±.7.5±..±..8±. (.%) Mean±S.D. Significantdiferencefrom control:,p<.5(mann-whitneyu-test) Significantdiferencefrom control: *,p<.5; **,p<.(student st-testoraspin-welchtest), ±.9.±5. 6.±. 77.±7. 5.±.5.9±..8±..±. 5.±6..5±..5±.6.6±.5 (.%)
7 5 Body weight (g) 5 5 GRNX 6 mg/kg GRNX 5 mg/kg GRNX, mg/kg Administration Day of gestation Fig.. BodyweightchangesduringthegestationperiodofdamstreatedoralywithGRNXin thestudyforefectsonembryo-fetaldevelopmentinrats. Significantdiferencefrom control: *,p<.5(student st-testoraspin-welchtest). Table7. CaesareansectiondataonratdamstreatedoralywithGRNXinthestudyforefects onembryo-fetaldevelopment 6 5, No.ofdams No.ofcorporalutea No.ofimplantations Implantationrate(%) No.oflivefetuses No.ofdeadfetuses Earlystage Latestage Deadfetuses(%) Sexratio [Male/(Male+ Female)] Bodyweight(g) Male Female 8 8.±.6.9±. 8.8±..8±.9.±..±..±. 6.8± 7..8±.7.6±..± ±.9 5.5±. 8.9± 9.6.8±..7±.8.7±.8.±..± 5..7±.5.6±.6.± ±.9 5.±. 8.8±.6.7±..8±..8±..±. 5.± 6.9.5±..9±.6.± ±.6.7±.8 8.±.5.9±.6.7±.9.7±.9.±..6± 5.5.5±.8.±..7±.8 Mean± S.D.
8 Table8. External,skeletalandvisceralobservationoffetusesobtainedfrom ratdamstreatedoralywithgrnxinthestudyfor efectsonembryo-fetaldevelopment No.offetuseswithexternalanomalies Dwarf Anophthalmia Kinkedtail No.offetuseswithskeletalanomalies Fusionofexoccipitalbone andcervicalvertebralarch Fusionofsternebrae No.offetuseswithskeletalvariations Thoracicvertebralbody Spliting Dumbbelshape Unilateralformation Unossification 5lumbarvertebrae Sacralization Cervicalrib Lumbarrib Shorteningofthrib Sternebra Asymmetry Spliting Degreeofossification No.offetuseswithvisceralanomalies Situsinversusviscerum totalizes Dilatationoflateralventricle Malpositionofpituitarygland anddeformityofthirdventricle Anophthalmia Thymicremnantinneck Dilatationofrenalpelvis Dilatationofrenalureter Aplasiaoftestisandepididymis (.%) (%) (8.7%) 8(6.9%) 7 6 (%) (%) 6(.8%) 5 * (.9%) :Normal Significantdiferencefrom control: *,p<.5(student st-testoraspin-welchtest) 5 (.%) (%) (6.6%) * (9.8%) 8, (%) (.6%) (.%) 7 5 (8.%) 5
9 Table9. CaesareansectiondataonrabbitdamstreatedintravenouslywithGRNXinthestudyforefects onembryo-fetaldevelopment No.ofdams No.ofdied No.ofabortion No.ofcorporalutea No.ofimplantations Implantationrate(%) No.oflivefetuses No.ofdeadfetuses Earlystage Latestage Deadfetuses(%) Sexratio [Male/(Male+ Female)] Bodyweight(g) Male Female 9.6±. 9.± ± ±.7.6±..±.5.±.8 6.±..5±.5 6.± ± ±. 8.±. 8.9± ±.7.6±.9.±.5.±.6 5.6± 8..5±.8 5.± ± a).6±. 8.±.8 78.±. 7.±.9 *.±..±.6.8±..5±.8.5±.7 6.8± ± 6.66 Mean± S.D. a) :Thenumbercontainsadeadanimal. Significantdiferencefrom control: *,p<.5(student st-testoraspin-welchtest) 5.7±.7 9.5±.9 89.±. 8.±.9.±.6.±.5.9±..± 5.7.5±..5± 5.7.6± 6... Body weight (kg) Administration GRNX 6.5 mg/kg GRNX.5 mg/kg GRNX 5 mg/kg Day of gestation Fig.. Bodyweightchangesduringthegestationperiodofdamstreatedintravenouslywith GRNXinthestudyforefectsonembryo-fetaldevelopmentinrabbits. Significantdiferencefrom control: *,p<.5(student st-testoraspin-welchtest).
10 Table. External,skeletalandvisceralobservationoffetusesobtainedfrom rabbitdamstreatedintravenouslywith GRNXinthestudyforefectsonembryo-fetaldevelopment No.offetuseswithexternalanomalies Forelimbarthrogryposis Omphalocele Brachyury No.offetuseswithskeletalanomalies Fusedsternebrae Sternoschisis Fusedrib Branchedrib Absentrib Nodulatedrib Fusedthoraciccentrum Absentthoracicarch Fusedcaudalvertebrae No.offetuseswithskeletalvariations Accessoryofsternebrae Incompleteossificationofrib Degreeofossification No.offetuseswithvisceralmajoranomalies Rightsubclavianarteryarising from aorticarch Ventricularseptum defect Persistenttruncusarteriosus Diaphragmatichernia Ectopickidney No.offetuseswithvisceralminoranomalies Thymicremnantinneck Supernumerarycoronaryarteryorifice Absentaccessorylobeinlung (.8%) (.5%) (.%) (%) (8.%) (%) (.%) (.8%) (.6%) (.5%) 6 :Normal a) :Theywerelitermates. Significantdiferencefrom control: #,p<.5; ##,p<.(mann-whitneyu-test).5 (.5%) (.5%) (%) (.8%) # (8.5%) (.7%) a) a) a) 8(6.%) # a) a) a) (%) (.5%) a) (.%) ## 6 ## III
11 In vitro in vivo In
12
13
日本化学療法学会雑誌第54巻第S-1号
β β β Key words β β I HP- -CD CHR RHC R R R R CHR R R R R RHC R R R CHR R R R RHC CHR R H CH CH Fig.. Structuralformulaofhydroxypropyl-β -cyclodextrin(hp-β -CD). CH n H β β β β Table-. Dosageandadministration(Singleadministrationstudy)
立命館21_松本先生.indd
2143-552010 1 2 () 1 2 3 456 78- Key Words 1 3 12007 2 3 508 19992008 1 23 4 43 2120107 4 2008 1992 2003 2005 1989 2008 4 2 2-1 10 4 4 6 5 4 5 2946 1 155 11 41 44 45 4 2-2 2003 1 21 2 1 3 4 5 6 7 3 2120107
立命館20_服部先生.indd
20 93-105 2010 2 () ' - 1 ( ) ( ' 2005) Key Words 2 1967 93 20 2010 1 94 1 ' 2002 2 2 1996 1996 1999 2 2 2 1993 1999 4 1 2 1985 1989 1986 1994 4 1 2 1 1 4 2 4 4 1 4 1966 4 10-1970 20 1993-1972 95 20 2010
1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70
14 2006 1 Key Words 2002 3 1 2 3 3 1 2 3 1969 1987 69 1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70 14 2006 1 15 71 72 1 22 6 32 9 200 6 3 1 2 2000 10 1 2003 10 2005 6 5 4
立命館16_坂下.indd
1669-792008 1 - ' 85- -108 ' Key words 1 2 2003 69 1620082 5 3 1990 1997 4 5 2001 1307 6 7 1 1 1 1996 100 2 1997 71 3 1998 71 4 1999 96 5 2000 95 6 2001 145 7 2002 191 8 2003 174 9 2004 120 10 2005 122
立命館人間科学研究No.10
1 77 5 Key words 1 23 3 11417 14310045 20022004 2 2003 20022005 20022004 2 10200511 3 2003 1152003 59 1995 3 32003 19932002 20032003 2005 20052005 4 1997 2000521986 2001 42001 3 1981 6 1 7 5 1000248 1632647
立命館21_川端先生.indd
21 119-132 2010 ( ) ' Key Words 119 21 2010 7 1962 2001 2001 2007 1982 1988 1997 2007 1997 1998 1863 1880 1 1998 1998 2001 1599 120 121 1599 1695 8 1695 1714 4 1714 1715 5 1715 100 1812 9 1812 1864 2001
立命館14_前田.indd
1499-1122007 1 ) ) ) ) ) (1) -- ) ) ) ) ) ) ( ) ) ' ) ) ) ) - 1) 2)' 3) Key words 19811994 1721 99 1420073 100 20012004 2005 2004 2002 33 34 10 1987 45 20002003 2002 1 1 2000 1 1 2001 2 200341 12004 2
立命館17_坂下.indd
1793-1052008 1 () -- -- - Key words 1 93 1720088 2 3 2003 15 1996 50 3040 2 3 4050 50 10 1980 1995 1950 1958 1968 1972 94 95 1987 4 4 70 3 3 1 2000 2001 4 1720088 96 2001 2003 2 1978 1990 1997 130 2 3
立命館人間科学研究No.10
49 00 7 Key words 980 995 50 0005 90 997 99 990 994 99 99 99990 99 996 988988 994 99 995 995 995 994 984 988 986 997 997 00 995 00 5 7 5 5 999 997 997 998 6 998 999 997 997 998 0040000 994 996 000 00 5
立命館19_椎原他.indd
191-132009 1 ( ) ' Key Words 1 11 12007 2007 200520062 201120062 7558 4009 1 1920098 2007 2 2000 028 2005 1999 12 1999 13 1968 2 3 '1992 2007 2001 20052001 1977 2005 2005 2007 21 21 22 461927 3 13 1920098
立命館人間科学研究No.10
61 10 1990 Key words 1 102005 11 62 2000 1 1920 10 1892 63 1 1 19 100 1914 100 1 1 20 1 2 102005 11 64 1946 21 4 1947 1949 1947 22 1 3 1956 1959 1958 2 1964 65 2 10 1975 7080 70 2 1 1987 1990 40 1989 1989
立命館19_徳田.indd
1991-1022009 1 2 () )--) 28 2827 1 2 Key Words 1 (1721 2000 20012001 20082009 91 1920098 92 20042004 2004 2001 12 2005 20082009 2005 3 1997 200820096 2007 2 20082009 93 20012001 12 2008 2009 19611966 1
CHEMOTHERAPY NOV. 1990
VOL.38 S-2 6, 8- Difluoro- 1-(2- fluoroethyl)- 1, 4- dihydro- 7-(4- methyl- 1- piperazinyl)- 4- oxo- 3- quinolinecarboxylic CHEMOTHERAPY NOV. 1990 VOL.38 S-2 Fig. 1. Body weight changes of male rats treated
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
日本化学療法学会雑誌第58巻第S-2号
μ Key words Streptococcus pneumoniae β Haemophilus influenzae β Moraxella Branhamella catarrhalis I F F H C SO H H O H N N N N F CO H O Fig.1. Chemicalstructureoftosufloxacintosilatehydrate. α Body weight
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...
取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -
CHEMOTHERAPY
CHEMOTHERAPY Fig.1 Effect of 6059-S on body weight changes in male rats Table 1 Effect of 6059-S on body weight changes in female rats :Mean }S.E. Table 2 Reproductive findings of rats treated with 6059
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
日本化学療法学会雑誌第56巻第3号
β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
CHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
日本化学療法学会雑誌第58巻第2号
Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito
１
10 1113 14 1516 1719 20 21 22 2324 25 2627 i 2829 30 31 32 33 3437 38 3941 42 4344 4547 48 4950 5152 53 5455 ii 56 5758 59 6061 iii 1 2 3 4 5 6 7 8 9 10 PFI 30 20 10 PFI 11 12 13 14 15 10 11 16 (1) 17
Fig. 1 Mean body weight changes of male rats administered cefaclor orally on fertility study Table. 1 Serum biochemical analysis in male rats administered cefaclor orally on fertility study The values
2 7 ( ) µ
EV200R I II III 1 2 3 4 5 6 7 8 9 10 1 2 3 11 4 5 12 6 13 1 2 14 3 4 15 5 16 1 2 17 3 18 4 5 19 6 20 21 22 123 456 123 456 23 1 2 24 3 4 25 5 3 26 4 5 6 27 7 8 9 28 29 30 31 32 1 2 33 3 4 34 1 35 2 1
（個別のテーマ） 放射線検査に関連した医療事故
- 131 - III - 132 - - 133 - III - 134 - - 135 - III - 136 - - 137 - III - 138 - - 139 - III - 140 - - 141 - III - 142 - - 143 - III - 144 - - 145 - III - 146 - - 147 - III - 148 - - 149 - III - 150 - -
（個別のテーマ） 薬剤に関連した医療事故
- 67 - III - 68 - - 69 - III - 70 - - 71 - III - 72 - - 73 - III - 74 - - 75 - III - 76 - - 77 - III - 78 - - 79 - III - 80 - - 81 - III - 82 - - 83 - III - 84 - - 85 - - 86 - III - 87 - III - 88 - - 89
訪問看護ステーションにおける安全性及び安定的なサービス提供の確保に関する調査研究事業報告書
1... 1 2... 3 I... 3 II... 3 1.... 3 2....15 3....17 4....19 5....25 6....34 7....38 8....48 9....58 III...70 3...73 I...73 1....73 2....82 II...98 4...99 1....99 2....104 3....106 4....108 5.... 110 6....
日本化学療法学会雑誌第57巻第1号
In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli
16 41 17 22 12 10
1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6
製品案内 価格表 2014/4/1
4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(
３．ごみの減量方法.PDF
- 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58
untitled
i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)
23 15961615 1659 1657 14 1701 1711 1715 11 15 22 15 35 18 22 35 23 17 17 106 1.25 21 27 12 17 420,845 23 32 58.7 32 17 11.4 71.3 17.3 32 13.3 66.4 20.3 17 10,657 k 23 20 12 17 23 17 490,708 420,845 23
平成１８年度「商品先物取引に関する実態調査」報告書
... 1.... 5-1.... 6-2.... 9-3.... 10-4.... 12-5.... 13-6.... 15-7.... 16-8.... 17-9.... 20-10.... 22-11.... 24-12.... 27-13... 29-14.... 32-15... 37-16.... 39-17.... 41-18... 43-19... 45.... 49-1... 50-2...
日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
四校＿目次～巻頭言.indd
107 25 1 2016 3 Key Words : A 114 67 58.84 Mann-Whitney 6 1. 2. 3. 4. 5. 6. I. 21 4 B 23 11 1 9 8 7 23456 108 25 1 2016 3 78 9 II. III. IV. 1. 24 4 A 114 2. 24 5 6 3. 4. 5. 3 42 5 16 6 22 5 4 4 4 3 6.